Literature DB >> 10731034

Activation of the A3 adenosine receptor affects cell cycle progression and cell growth.

R Brambilla1, F Cattabeni, S Ceruti, D Barbieri, C Franceschi, Y C Kim, K A Jacobson, K N Klotz, M J Lohse, M P Abbracchio.   

Abstract

The A3 adenosine receptor has been implicated in modulation of cell growth. As a first step to the characterization of the underlying mechanisms, we exposed Chinese hamster ovary (CHO) cells transfected with the human A3 receptor (A3R-CHO) to selective A3 receptor ligands. At micromolar concentrations, the A3 agonists N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA) and its 2-chloro derivative Cl-IB-MECA reduced cell number, with no effects on either parental CHO cells (not expressing any adenosine receptor), or CHO cells transfected with the human A1 receptor. Cl-IB-MECA also reduced cell number in the human HEK293 cell line transfected with the human A3 receptor cDNA as opposed to the respective untransfected wild-type cells. In A3R-CHO, agonist-induced effects were antagonized by nanomolar concentrations of A3 antagonists, including the triazoloquinazoline derivative MRS 1220, the dihydropyridine derivative MRS 1191, and the triazolonaphthyridine derivative L-249,313. A3 agonist-induced effects were not due to modulation of cell adhesion, nor to necrosis or apoptosis. Growth curves revealed highly impeded growth, and flow-cytometric analysis showed markedly reduced bromodeoxyuridine incorporation into nuclei. The effect on cell cycle was completely antagonized by MRS1191. Hence, activation of the human A3 receptor in A3R-CHO results in markedly impaired cell cycle progression, suggesting an important role for this adenosine receptor subtype in cell cycle regulation and cell growth.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10731034     DOI: 10.1007/s002109900186

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  18 in total

1.  Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line.

Authors:  S Merighi; K Varani; S Gessi; E Cattabriga; V Iannotta; C Ulouglu; E Leung; P A Borea
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

2.  Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells.

Authors:  S Gessi; K Varani; S Merighi; A Morelli; D Ferrari; E Leung; P G Baraldi; G Spalluto; P A Borea
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

3.  A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation.

Authors:  M L Trincavelli; D Tuscano; M Marroni; A Falleni; V Gremigni; S Ceruti; M P Abbracchio; K A Jacobson; F Cattabeni; C Martini
Journal:  Mol Pharmacol       Date:  2002-12       Impact factor: 4.436

4.  Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety.

Authors:  Philippe Van Rompaey; Kenneth A Jacobson; Ariel S Gross; Zhan-Guo Gao; Serge Van Calenbergh
Journal:  Bioorg Med Chem       Date:  2005-02-15       Impact factor: 3.641

5.  Effects of synthetic A3 adenosine receptor agonists on cell proliferation and viability are receptor independent at micromolar concentrations.

Authors:  Petr Mlejnek; Petr Dolezel; Ivo Frydrych
Journal:  J Physiol Biochem       Date:  2012-11-27       Impact factor: 4.158

6.  Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms.

Authors:  Anke C Schiedel; Svenja K Lacher; Carsten Linnemann; Percy A Knolle; Christa E Müller
Journal:  Purinergic Signal       Date:  2013-01-29       Impact factor: 3.765

7.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

8.  p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA.

Authors:  Seong Gon Kim; Gnana Ravi; Carsten Hoffmann; Yun Jin Jung; Min Kim; Aishe Chen; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2002-03-01       Impact factor: 5.858

9.  The A3 adenosine receptor induces cytoskeleton rearrangement in human astrocytoma cells via a specific action on Rho proteins.

Authors:  M P Abbracchio; A Camurri; S Ceruti; F Cattabeni; L Falzano; A M Giammarioli; K A Jacobson; L Trincavelli; C Martini; W Malorni; C Fiorentini
Journal:  Ann N Y Acad Sci       Date:  2001-06       Impact factor: 5.691

10.  Mitochondrial and caspase pathways are involved in the induction of apoptosis by IB-MECA in ovarian cancer cell lines.

Authors:  Hamideh Abedi; Mahmoud Aghaei; Mojtaba Panjehpour; Sima Hajiahmadi
Journal:  Tumour Biol       Date:  2014-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.